GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regent Pacific Group Ltd (HKSE:00575) » Definitions » Quality Rank

Regent Pacific Group (HKSE:00575) Quality Rank


View and export this data going back to 1997. Start your Free Trial

What is Regent Pacific Group Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Regent Pacific Group Quality Rank Related Terms

Thank you for viewing the detailed overview of Regent Pacific Group's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Regent Pacific Group Business Description

Traded in Other Exchanges
Address
5 Queen's Road Central, 8th Floor, Henley Building, Hong Kong, HKG
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Its geographical segments are China, Europe, Hong Kong, and Taiwan.
Executives
Mellon James
Galloway Limited
2464344 Ontario Inc. 2101 Beneficial owner
Caravel Ds Fund Ltd. 2101 Beneficial owner